Rein Therapeutics (RNTX) Equity Ratio (2016 - 2025)
Rein Therapeutics (RNTX) has disclosed Equity Ratio for 10 consecutive years, with 0.86 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 5.88% to 0.86 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.86, a 5.88% decrease, with the full-year FY2024 number at 0.87, down 5.68% from a year prior.
- Equity Ratio was 0.86 for Q3 2025 at Rein Therapeutics, up from 0.84 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.95 in Q1 2021 to a low of 0.83 in Q1 2023.
- A 5-year average of 0.89 and a median of 0.9 in 2022 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: skyrocketed 98.06% in 2021, then decreased 9.54% in 2025.
- Rein Therapeutics' Equity Ratio stood at 0.91 in 2021, then fell by 6.55% to 0.85 in 2022, then grew by 9.58% to 0.93 in 2023, then dropped by 5.68% to 0.87 in 2024, then dropped by 1.66% to 0.86 in 2025.
- Per Business Quant, the three most recent readings for RNTX's Equity Ratio are 0.86 (Q3 2025), 0.84 (Q2 2025), and 0.87 (Q1 2025).